Telehealth companies offering GLP-1 weight loss drugs face scrutiny over patient screening and monitoring

Telehealth companies are facing heightened scrutiny over inadequate patient screening and monitoring practices before prescribing GLP-1 weight loss drugs.

Objective Facts

The rapid expansion of telehealth has facilitated increased access to GLP-1 weight loss medications, but has also led to a surge in medication errors, adverse events, and concerns about inadequate patient evaluation and follow-up. According to Marc-Andre Cornier, the problem is there aren't criteria written by a government agency or a medical society to determine which providers are treating patients appropriately and which aren't. Patients with a history of pancreatitis should be counseled about potential complications, as should those with gastroparesis or susceptibility to medullary thyroid cancer. Surveys show that 67% of primary care physicians have concerns that third-party telehealth GLP-1 prescribing may put patients at risk. FDA Commissioner Marty Makary has declared this a 'new era of enforcement' with heightened scrutiny of telehealth companies' claims and prescribing practices.

Left-Leaning Perspective

Left-leaning and clinical voices emphasize the safety risks of inadequate telehealth screening and monitoring. The KFF Health News and medical sources cited in the major June 2026 reporting have documented the concern: medication errors exploded from 2,000 reports in 2020 to 25,000 in 2025, with frequent issues including administration of incorrect doses and prescribing errors. Dr. Marc-Andre Cornier at the Medical University of South Carolina told KFF Health News that there aren't criteria written by government agencies or medical societies to determine which providers are treating patients appropriately. The Omada Health survey of physicians found that 67% of primary care physicians expressed concern about third-party telehealth prescribing putting patients at risk, with 56% concerned about overprescribing and 50% about compromised continuity of care. Progressive medical organizations argue the core issue is inadequate monitoring infrastructure. Current telehealth models focus primarily on prescribing without adequate nutrition, exercise, and behavioral change guidance, according to reporting in MedCity News. The Journal of Medical Internet Research noted that one of the biggest potential drawbacks of telehealth for GLP-1s is the lack of ongoing clinical support for patients, and while participants reduced weight by significant amounts, 40% of that weight was lean tissue, and only 3 of 12 studies involved a registered dietitian. Additionally, Martin Makary called the FDA's enforcement moves against misleading advertising 'overdue' and an 'action to correct decades of regulatory failure'. Left-leaning coverage largely omits or downplays affordability arguments and instead frames telehealth screening gaps as a consumer protection issue requiring stronger FDA oversight. Progressive sources do not substantially cover the countervailing argument that stricter regulations might reduce access for lower-income patients who cannot afford $1,000+ monthly branded drugs.

Right-Leaning Perspective

Right-leaning and industry perspectives prioritize access and innovation while accepting that some oversight is warranted for genuinely false marketing claims. The Pacific Research Institute, a conservative think tank, released a June 2026 brief emphasizing that GLP-1s are promising medical breakthroughs but allowing unauthorized mass marketing outside FDA safeguards creates safety risks and undermines healthcare trust. This framing accepts FDA enforcement against clearly deceptive practices (like claiming compounded drugs are FDA-approved equivalent) while implicitly questioning whether broader restrictions on access are justified. Telehealth industry figures and some medical providers defend compounding as a necessary access solution. Dr. Taylor Kantor of Ivim Health told FierceHealthcare that the administration is focused on reducing healthcare costs, compounded medications serve as a safe and effective way to do this, and affordability issues with branded drugs persist at over $1,000 monthly versus compounded alternatives under $200. Hims & Hers CEO Andrew Dudum stated the company would continue offering access to treatments "as allowed by law to meet patient needs" and noted ongoing supply constraints with branded drugs. The right-leaning framing emphasizes that TrumpRx offers semaglutide tablets at $149-$299 versus $1,349 list price, providing consumer choice and cost reduction through direct-to-consumer models. Right-leaning coverage does not substantially engage with the medical community's documented concerns about inadequate patient screening and monitoring, instead focusing on cost competition and the risk of FDA overreach restricting market-based solutions. Conservative outlets frame the issue primarily through a lens of price transparency and access rather than clinical safety protocols.

Deep Dive

The core tension in this story stems from a genuine market failure in prescribing oversight colliding with real access barriers. Telehealth companies exploded onto the GLP-1 market because of three factors: drug shortages of branded medications, prices exceeding $1,000 per month, and insurance coverage gaps. Telehealth companies act as intermediaries between customers and compounding pharmacies that create GLP-1s from overseas-sourced ingredients not reviewed by FDA, in an environment that is 'very much uncontrolled and poorly, if at all, regulated'. At the same time, GLP-1 drugs cost around $1,000 a month, even cheaper versions cost hundreds monthly, and high costs threaten budgets of insurers and states. What each perspective gets right: Medical professionals accurately identify real screening and monitoring gaps. Adverse event reports consistently cite administration of incorrect doses, communication problems, and prescribing errors. 56% of primary care physicians report concerns about overprescribing and 50% about continuity of care. These are not hypothetical risks. Simultaneously, telehealth industry advocates correctly note that despite recent price reductions, most commercial plans did not cover obesity indications historically, meaning insured patients often paid full cost out of pocket, but in early 2026 monthly prices fell below $350 without insurance, opening new access pathways outside traditional insurance. Restricting compounding access without ensuring affordable branded alternatives does force patients to choose between cost and safety. What each perspective omits or downplays: Medical coverage does not substantially address why screening standards were never established despite decades of GLP-1 use for diabetes. The absence of FDA criteria for telehealth GLP-1 prescribing reflects regulatory gaps that predate the current wave of telehealth startups. Right-leaning coverage downplays that medication errors surged from 2,000 reports in 2020 to 25,000 in 2025, treating this as merely a marketing problem solvable through enforcement against false claims rather than as evidence of inadequate clinical infrastructure in telehealth models. Neither side adequately grapples with whether the solution is to improve telehealth monitoring protocols or to restrict access to in-person prescribers only—a choice with enormous equity implications. What to watch: The resolution will depend on whether the recent price reductions to approximately $350 monthly and $149 at starting doses make out-of-pocket payment a realistic option for previously unaffordable patients, and whether these lower prices persist. A Medicare bridge payment demonstration begins July 2026 with $50/month copays, but Medicare's statutory prohibition on covering weight loss drugs hasn't changed, meaning coverage goes away if demonstrations end without Congressional action. If prices remain low and access improves through TrumpRx and manufacturer direct-to-consumer models, the political pressure for compounded GLP-1s may ease. If they revert to high prices, enforcement will likely face pushback from patient advocates. The unresolved question is whether better telehealth monitoring standards can be established quickly enough to address safety gaps while access expands, or whether the regulatory approach will continue to prioritize supply-side enforcement.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

Telehealth companies offering GLP-1 weight loss drugs face scrutiny over patient screening and monitoring

Telehealth companies are facing heightened scrutiny over inadequate patient screening and monitoring practices before prescribing GLP-1 weight loss drugs.

Jun 14, 2026· Updated Jun 17, 2026
What's Going On

The rapid expansion of telehealth has facilitated increased access to GLP-1 weight loss medications, but has also led to a surge in medication errors, adverse events, and concerns about inadequate patient evaluation and follow-up. According to Marc-Andre Cornier, the problem is there aren't criteria written by a government agency or a medical society to determine which providers are treating patients appropriately and which aren't. Patients with a history of pancreatitis should be counseled about potential complications, as should those with gastroparesis or susceptibility to medullary thyroid cancer. Surveys show that 67% of primary care physicians have concerns that third-party telehealth GLP-1 prescribing may put patients at risk. FDA Commissioner Marty Makary has declared this a 'new era of enforcement' with heightened scrutiny of telehealth companies' claims and prescribing practices.

Left says: Medical experts and primary care physicians argue that virtual-only care is insufficient for safe GLP-1 prescribing and that telehealth companies are not adequately screening patients before prescriptions. The problem is compounded by telehealth models that focus primarily on prescribing without providing necessary nutrition and behavioral guidance.
Right says: Conservative voices emphasize that FDA enforcement against unauthorized compounders protects patient safety and prevents companies from bypassing FDA safeguards, while telehealth industry advocates contend compounded drugs provide necessary affordable access when branded options cost over $1,000 monthly.
✓ Common Ground
Both sides acknowledge that some telehealth firms have suggested compounded products were comparable to FDA-approved medications when compounded drugs are not reviewed by FDA for safety, effectiveness, or quality before being sold.
Regulatory voices across the spectrum agree that compounding can serve a legitimate purpose during shortages or for specific patient needs. FDA Commissioner Marty Makary stated that compounding serves legitimate purposes for overcoming shortages or meeting unique patient needs, but compounders should not use the process to circumvent the FDA's approval process.
There is agreement that medication errors and adverse events related to GLP-1 prescribing have increased substantially. Both safety-focused medical researchers and regulatory voices acknowledge that the rapid expansion of telehealth prescribing compounded GLP-1s has resulted in a surge of medication errors and adverse events.
Stakeholders on both sides recognize that GLP-1 drugs represent important medical breakthroughs. The Pacific Research Institute acknowledged that GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling with diabetes, obesity and other chronic illnesses.
Objective Deep Dive

The core tension in this story stems from a genuine market failure in prescribing oversight colliding with real access barriers. Telehealth companies exploded onto the GLP-1 market because of three factors: drug shortages of branded medications, prices exceeding $1,000 per month, and insurance coverage gaps. Telehealth companies act as intermediaries between customers and compounding pharmacies that create GLP-1s from overseas-sourced ingredients not reviewed by FDA, in an environment that is 'very much uncontrolled and poorly, if at all, regulated'. At the same time, GLP-1 drugs cost around $1,000 a month, even cheaper versions cost hundreds monthly, and high costs threaten budgets of insurers and states.

What each perspective gets right: Medical professionals accurately identify real screening and monitoring gaps. Adverse event reports consistently cite administration of incorrect doses, communication problems, and prescribing errors. 56% of primary care physicians report concerns about overprescribing and 50% about continuity of care. These are not hypothetical risks. Simultaneously, telehealth industry advocates correctly note that despite recent price reductions, most commercial plans did not cover obesity indications historically, meaning insured patients often paid full cost out of pocket, but in early 2026 monthly prices fell below $350 without insurance, opening new access pathways outside traditional insurance. Restricting compounding access without ensuring affordable branded alternatives does force patients to choose between cost and safety.

What each perspective omits or downplays: Medical coverage does not substantially address why screening standards were never established despite decades of GLP-1 use for diabetes. The absence of FDA criteria for telehealth GLP-1 prescribing reflects regulatory gaps that predate the current wave of telehealth startups. Right-leaning coverage downplays that medication errors surged from 2,000 reports in 2020 to 25,000 in 2025, treating this as merely a marketing problem solvable through enforcement against false claims rather than as evidence of inadequate clinical infrastructure in telehealth models. Neither side adequately grapples with whether the solution is to improve telehealth monitoring protocols or to restrict access to in-person prescribers only—a choice with enormous equity implications.

What to watch: The resolution will depend on whether the recent price reductions to approximately $350 monthly and $149 at starting doses make out-of-pocket payment a realistic option for previously unaffordable patients, and whether these lower prices persist. A Medicare bridge payment demonstration begins July 2026 with $50/month copays, but Medicare's statutory prohibition on covering weight loss drugs hasn't changed, meaning coverage goes away if demonstrations end without Congressional action. If prices remain low and access improves through TrumpRx and manufacturer direct-to-consumer models, the political pressure for compounded GLP-1s may ease. If they revert to high prices, enforcement will likely face pushback from patient advocates. The unresolved question is whether better telehealth monitoring standards can be established quickly enough to address safety gaps while access expands, or whether the regulatory approach will continue to prioritize supply-side enforcement.

◈ Tone Comparison

Medical and left-leaning coverage uses urgent language around "explosions" in medication errors and emphasizes systemic failures ("no standard of care"). Right-leaning and industry coverage uses language of "innovation," "access," and "affordability," framing regulatory enforcement narrowly as targeting false marketing rather than acknowledging underlying screening gaps. The fundamental tone difference is whether the glass is half-empty (safety infrastructure failing) or half-full (market mechanisms and industry maturation addressing problems).